Apimeds Pharmaceuticals US (APUS) Assets Average (2025 - 2026)
Apimeds Pharmaceuticals US's (APUS) quarterly Assets Average came in at $145.9 million in Q2 2026, up 2600.27% on a YoY basis from $5.4 million in Q2 2025, and up 68.25% quarter-over-quarter from $86.7 million in Q4 2025.
Powered by 
Analysis
Apimeds Pharmaceuticals US (APUS) Assets Average (2025 - 2026) Analysis & Trends
Apimeds Pharmaceuticals US (APUS) has reported Assets Average for 2 consecutive years, with $145.9 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Assets Average rose 2600.27% year-over-year to $145.9 million; the trailing twelve-month figure through Jun 2026 stood at $145.9 million (up 2600.27% YoY), and the FY2025 full-year result was $82.1 million, up 37634.85% from the prior year.
- Assets Average grew to $145.9 million in Q2 2026 per APUS's latest filing, from $86.7 million in the prior quarter.
- Across five years, Assets Average topped out at $145.9 million in Q2 2026 and bottomed at $136480.5 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 94.07 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 52.82 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 26.95 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 41.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 11.22 Bn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 5.34 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 30.78 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 5.51 Bn |
| 10 | Apimeds Pharmaceuticals US | 3.79 Mn | 3.79 Mn | - | 145.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 145.90 Mn |
| Dec 31, 2025 | 86.72 Mn |
| Sep 30, 2025 | 9.90 Mn |
| Jun 30, 2025 | 5.40 Mn |
| Mar 31, 2025 | 136,480.50 |